SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Yilmaz Aylin)
 

Sökning: WFRF:(Yilmaz Aylin) > (2004) > Cerebrospinal fluid...

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz, Aylin, 1974 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för infektionssjukdomar,Institute of Internal Medicine, Dept of Infectious Diseases
Ståhle, Lars (författare)
Hagberg, Lars, 1951 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för infektionssjukdomar,Institute of Internal Medicine, Dept of Infectious Diseases
visa fler...
Svennerholm, Bo, 1949 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för laboratoriemedicin, Avdelningen för klinisk virologi,Institute of Laboratory Medicine, Dept of Clinical Virology
Fuchs, Dietmar (författare)
Gisslén, Magnus, 1962 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för infektionssjukdomar,Institute of Internal Medicine, Dept of Infectious Diseases
visa färre...
 (creator_code:org_t)
2009-07-08
2004
Engelska.
Ingår i: Scandinavian journal of infectious diseases. - : Informa UK Limited. - 0036-5548 .- 1651-1980. ; 36:11-12, s. 823-8
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Our objective was to study the effect of lopinavir/ritonavir on cerebrospinal fluid (CSF) viral load as part of an antiretroviral combination treatment for HIV-1 infected individuals, and to determine the steady-state concentrations of lopinavir in CSF in relationship to plasma concentrations. Paired CSF and plasma samples from 12 antiretroviral-naïve HIV-1 infected patients starting combination therapy containing lopinavir/ritonavir were collected at baseline, and during treatment at a first follow-up at median 3.0 months (range 2.6-6.0 months), and at a second follow-up at median 12.1 months (range 6.0-16.5 months). Levels of HIV-1 RNA, CD4+ T-cell count, beta2-microglobulin, neopterin, and lopinavir concentration were analysed. In addition, CSF and plasma lopinavir concentrations in 4 patients already on combination therapy including lopinavir/ritonavir were analysed. Nine of 11 patients had undetectable viral load in CSF and 5/11 in plasma at the first follow-up. At the second follow-up 7/7 had undetectable viral load in CSF and 9/9 in plasma. Intrathecal immunoactivation, measured by neopterin and beta2-microglobulin, decreased significantly both in CSF and serum. The total CSF concentrations of lopinavir were of the same order of magnitude as the unbound concentrations in plasma. Lopinavir mean (+/-SD) concentrations were 42.1 (+/-31.5) nM in CSF and 52.7 (+/-25.2) nM unbound in plasma. We found that antiretroviral combination therapy including lopinavir/ritonavir substantially decreases the viral load, both in CSF and plasma, as well as the intrathecal immunoactivation, measured by beta2-microglobulin and neopterin. CSF concentrations of lopinavir were low, but probably sufficient to have a virological effect.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Microbiology in the medical area (hsv//eng)

Nyckelord

Adult
Anti-HIV Agents
administration & dosage
blood
therapeutic use
Antiretroviral Therapy
Highly Active
CD4 Lymphocyte Count
Female
HIV Infections
blood
cerebrospinal fluid
drug therapy
HIV Protease Inhibitors
administration & dosage
blood
therapeutic use
HIV-1
drug effects
Humans
Male
Middle Aged
Neopterin
blood
Pyrimidinones
administration & dosage
blood
therapeutic use
RNA
Viral
blood
cerebrospinal fluid
Ritonavir
administration & dosage
therapeutic use
Viral Load

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy